top of page
Biodegradable Medical Polymers
Working with our partner PolymerPharm, NovoMed has taken steps to enhance the efficacy of phage therapy via a recently developed technology called amino add-based biodegradable polymers. Invented by two distinguished Georgian scientists - Prof. Zemphira Alavidze, PhD and Prof. Ramaz Katsarava, PhD., biodegrable polymers are applicable in many areas in medicine including use in wound care, treatment of osteomyelitis and surgical infections.
PhagoBioDerm is a medicated wound dressing acting in drug sustained/controlled release fashion made of biodegradable and highly biocompatible polymer, containing bacteriophages' cocktail as an antibacterial agent.
PhagoBioDerm is a biocomposite material based on biodegradable poly(ester amide) matrix and containing complex of bacteriophages against 5 general suppurative microorganisms (Pseudomonas aeruginosa, E.coli, Staphylococcus, Streptococcus and Proteus) as bactericidal substances, and acting in drug sustained/controlled release fashion. PhagoBioDerm contains also antibiotic ciprofloxacin, painkiller Benzocain and proteolytic enzymes (a-Chymotrypsin or Trypsin).
Therapeutic effect of the preparation is related to several factors:
1. Polymeric film protects the wound surface from intensive moisture losses via uncontrollable evaporation, and from external actions like mechanical irritation, microbial invasion, etc. A high biodegradation rate provides a sufficient amount of polymeric debris (biodegradation products) that accelerate macrophages for their production of cell growth factors, accelerate the tissue regeneration.
2. A-Chymotrypsin (or Trypsin) promotes the sanitation of the wound surface and erodes polymeric film, thereby providing in that way with sustained/controlled release of bioactive substances into surrounding tissues.
3. Bacteriophages and antibiotic (can be varied) suppress bacterial flora, bacteriophages suppress the flora resistant to antibiotics.
4. Benzocain causes local painkiller effect.
A high therapeutic effect of the preparation is achieved owing to a high local concentration of active substances for a long period at a low integral dose of the drug(s) that minimizes possible adverse effects.
PhagoBioDerm is an innovative product and has no analogues in world pharmacy. It has been developed by a group of Georgian chemists and microbiologists since 1995. PhagoBioDerm is an anti-microbial, antiseptic, accelerated wound healing remedy. It is a highly efficacious medical device with a prolonged action used for healing various infected wounds and sores, as well as, dental gum diseases. It contains biodegradable polymers (composed of naturally occurring and non-toxic building blocks) and a complex of bacteriophages as bactericidal substances.
Scientific Literature
Recent Clinical Studies
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy
Wright, A., Hawkins, CH., Anggard, E.E.& Harper, D.R.
UCL Ear Institute and Royal National Throat, Nose and Ear Hospital, Grays Inn Road, London, and Biocontrol Limited, BioCity, Pennyfoot Street, Nottingham,
UK Chn. Otolaryngol. 2009, 34, 349-357
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I
safety trial
D.D. Rhoads. MT (ASCP), Laboratory Researcher; R.D. Wolcott, MD, Director; M.A. Kuskowski, PhD, Associate Professor, Department of Psychiatry, University of Minnesota, Minneapolis, US; B.M. Wolcott, Research Technician; L.S. Ward, PhD, Director of Research, Glanbia Research and Development Center, Twin Falls, Idaho, US; A. Sulalcvelidze, PhD, Chief Scientist, Intralytix, Baltimore, MD
JOURNAL OF WOUND CARE VOL 1 8 . NO 6, JUNE 2009
bottom of page